JP2024519545A - B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma - Google Patents

B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma Download PDF

Info

Publication number
JP2024519545A
JP2024519545A JP2023573168A JP2023573168A JP2024519545A JP 2024519545 A JP2024519545 A JP 2024519545A JP 2023573168 A JP2023573168 A JP 2023573168A JP 2023573168 A JP2023573168 A JP 2023573168A JP 2024519545 A JP2024519545 A JP 2024519545A
Authority
JP
Japan
Prior art keywords
bcma
cell
cells
subject
specific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573168A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519545A5 (cg-RX-API-DMAC7.html
Inventor
ザ サード,ホーマー アダムス
ベローナ,ラルカ
ピー. カーター,アーノン
フレデリック エルデリン,エリック
Original Assignee
ヤンセン バイオテツク,インコーポレーテツド
アカデミッシュ メディッシュ セントラム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク,インコーポレーテツド, アカデミッシュ メディッシュ セントラム filed Critical ヤンセン バイオテツク,インコーポレーテツド
Publication of JP2024519545A publication Critical patent/JP2024519545A/ja
Publication of JP2024519545A5 publication Critical patent/JP2024519545A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2023573168A 2021-05-28 2022-05-26 B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma Pending JP2024519545A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163194470P 2021-05-28 2021-05-28
US63/194,470 2021-05-28
US202163209694P 2021-06-11 2021-06-11
US63/209,694 2021-06-11
PCT/EP2022/064362 WO2022248642A1 (en) 2021-05-28 2022-05-26 Bcma as a target for t cell redirecting antibodies in b cell lymphomas

Publications (2)

Publication Number Publication Date
JP2024519545A true JP2024519545A (ja) 2024-05-15
JP2024519545A5 JP2024519545A5 (cg-RX-API-DMAC7.html) 2025-05-26

Family

ID=82115891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573168A Pending JP2024519545A (ja) 2021-05-28 2022-05-26 B細胞リンパ腫におけるt細胞リダイレクト抗体の標的としてのbcma

Country Status (10)

Country Link
US (1) US20220411525A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347039A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024519545A (cg-RX-API-DMAC7.html)
KR (1) KR20240014482A (cg-RX-API-DMAC7.html)
CN (1) CN119679935A (cg-RX-API-DMAC7.html)
AU (1) AU2022281104A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024822A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221399A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014139A (cg-RX-API-DMAC7.html)
WO (1) WO2022248642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BLOOD ADV, vol. vol. 4(18), JPN6026020764, 21 September 2020 (2020-09-21), pages 4538 - 4549, ISSN: 0005869186 *
BLOOD, vol. vol. 132(Supplement_1), JPN6026020763, 2018, pages 3225, ISSN: 0005869185 *
BLOOD, vol. vol. 134(Supplement_1), JPN6026020762, 2019, pages 1580, ISSN: 0005869184 *

Also Published As

Publication number Publication date
BR112023024822A2 (pt) 2024-02-20
WO2022248642A1 (en) 2022-12-01
US20220411525A1 (en) 2022-12-29
CA3221399A1 (en) 2022-12-01
CN119679935A (zh) 2025-03-25
EP4347039A1 (en) 2024-04-10
KR20240014482A (ko) 2024-02-01
MX2023014139A (es) 2023-12-13
AU2022281104A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
TW202208429A (zh) 用於治療多發性骨髓瘤之方法
US20240209061A1 (en) Fusion proteins and uses thereof
AU2016369537A1 (en) Antibody molecules to PD-1 and uses thereof
CN110312525A (zh) T细胞重定向多功能抗体与免疫检查点调节剂的组合及其用途
JP2016534090A (ja) Cd38アゴニストの医学的使用
TW202340247A (zh) 結合nkg2d、cd16、及5t4之蛋白質
CN112292399A (zh) 抗cd27抗体及其用途
WO2022058445A1 (en) Methods for treating multiple myeloma
JP2023517794A (ja) 抗tnfr2抗体及びその使用
US20220411525A1 (en) Bcma as a target for t cell redirecting antibodies in b cell lymphomas
EP3737410A1 (en) Anti-siglec-7 antibodies having reduced effector function
CA3253669A1 (en) Anti-CD39 antibodies and their use
JP2024097985A (ja) 抗gitr抗体およびその使用
JP7533330B2 (ja) Pd-1/cd3二重特異性タンパク質による血液がん治療
CN118043070A (zh) Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标
CA3211179A1 (en) Anti-human cxcr5 antibody and uses thereof
RU2788092C2 (ru) Молекулы антител к pd-1 и их применения
HK40103924A (en) Methods of cancer treatment using anti-tigit antibodies in combination with anti-pd1 antibodies
EA050839B1 (ru) Способы лечения множественной миеломы
HK40092079A (en) Anti-tnfr2 antibody and uses thereof
CA3124168A1 (en) Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20241218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260526